Options for improving effectiveness of rotavirus vaccines in developing countries

Marion S. Tissera, Daniel Cowley, Nada Bogdanovic-Sakran, Melanie L. Hutton, Dena Lyras, Carl D. Kirkwood, Jim P. Buttery

Research output: Contribution to journalReview ArticleResearchpeer-review

6 Citations (Scopus)

Abstract

Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90%. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60% in developing countries, but have been proven life-saving. Bridging this "efficacy gap" offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.

Original languageEnglish
Pages (from-to)921-927
Number of pages7
JournalHuman Vaccines & Immunotherapeutics
Volume13
Issue number4
DOIs
Publication statusPublished - 3 Apr 2017

Keywords

  • adjuvant
  • developing countries
  • effectiveness
  • efficacy
  • immunogenicity
  • rotavirus
  • vaccine

Cite this

Tissera, Marion S. ; Cowley, Daniel ; Bogdanovic-Sakran, Nada ; Hutton, Melanie L. ; Lyras, Dena ; Kirkwood, Carl D. ; Buttery, Jim P. / Options for improving effectiveness of rotavirus vaccines in developing countries. In: Human Vaccines & Immunotherapeutics. 2017 ; Vol. 13, No. 4. pp. 921-927.
@article{9016e45a0db24ba384298b5068036d09,
title = "Options for improving effectiveness of rotavirus vaccines in developing countries",
abstract = "Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85{\%} of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90{\%}. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60{\%} in developing countries, but have been proven life-saving. Bridging this {"}efficacy gap{"} offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.",
keywords = "adjuvant, developing countries, effectiveness, efficacy, immunogenicity, rotavirus, vaccine",
author = "Tissera, {Marion S.} and Daniel Cowley and Nada Bogdanovic-Sakran and Hutton, {Melanie L.} and Dena Lyras and Kirkwood, {Carl D.} and Buttery, {Jim P.}",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/21645515.2016.1252493",
language = "English",
volume = "13",
pages = "921--927",
journal = "Human Vaccines & Immunotherapeutics",
issn = "2164-5515",
publisher = "Taylor & Francis",
number = "4",

}

Options for improving effectiveness of rotavirus vaccines in developing countries. / Tissera, Marion S.; Cowley, Daniel; Bogdanovic-Sakran, Nada; Hutton, Melanie L.; Lyras, Dena; Kirkwood, Carl D.; Buttery, Jim P.

In: Human Vaccines & Immunotherapeutics, Vol. 13, No. 4, 03.04.2017, p. 921-927.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Options for improving effectiveness of rotavirus vaccines in developing countries

AU - Tissera, Marion S.

AU - Cowley, Daniel

AU - Bogdanovic-Sakran, Nada

AU - Hutton, Melanie L.

AU - Lyras, Dena

AU - Kirkwood, Carl D.

AU - Buttery, Jim P.

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90%. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60% in developing countries, but have been proven life-saving. Bridging this "efficacy gap" offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.

AB - Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90%. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60% in developing countries, but have been proven life-saving. Bridging this "efficacy gap" offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.

KW - adjuvant

KW - developing countries

KW - effectiveness

KW - efficacy

KW - immunogenicity

KW - rotavirus

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85021308312&partnerID=8YFLogxK

U2 - 10.1080/21645515.2016.1252493

DO - 10.1080/21645515.2016.1252493

M3 - Review Article

VL - 13

SP - 921

EP - 927

JO - Human Vaccines & Immunotherapeutics

JF - Human Vaccines & Immunotherapeutics

SN - 2164-5515

IS - 4

ER -